Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period of July 2022. The report, dated July 21, 2022, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The document serves as a cover for a press release but does not include the text of that release. Consequently, no guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided content.
Investor Verification Checklist
- Review the full text of the press release dated July 21, 2022 (Exhibit 99.1), which is referenced but not included in this summary.
- Verify the specific clinical or corporate developments announced in the press release to understand the context of this filing.
- Check subsequent filings for any updates or superseding information related to the July 2022 announcement.